GHK-Cu vs BPC-157: Research Comparison | Peptide Intel Hub

GHK-Cu is a tripeptide (Gly-His-Lys) complexed with a copper(II) ion. Its proposed mechanism in research models centres on copper-mediated signalling effects on collagen synthesis, matrix-metalloproteinase activity and antioxidant-axis modulation in skin and connective-tissue research.

BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of human gastric juice protein. Its proposed mechanism centres on multi-axis tissue-repair signalling — angiogenic-axis modulation, growth-factor-axis interaction and broader repair-pathway activation.

GHK-Cu's pharmacology depends critically on the copper-ion coordination — the apo-peptide and the copper complex have distinct research profiles. Published work characterises effects on a range of downstream gene-expression programmes relevant to skin and connective-tissue research.

BPC-157 does not act through a single canonical receptor — published research suggests interactions with multiple growth-factor and angiogenic pathways simultaneously, which is the proposed basis for its broader tissue-repair profile.

GHK-Cu is a short copper-bound tripeptide; research administration routes include topical, subcutaneous and intramuscular. Topical formulations are particularly well-characterised in skin-research literature.

BPC-157 is a 15-residue peptide with notable stability in gastric conditions — oral, subcutaneous and intraperitoneal research-administration routes are documented.

GHK-Cu is widely used in skin-research, wound-healing, hair-follicle and connective-tissue research models. The copper-coordinated tripeptide structure makes it a common reference compound in matrix-metalloproteinase research.

BPC-157 is widely used in research models of tendon, ligament, muscle, gastrointestinal and skin tissue repair, and in angiogenesis research. The multi-axis profile gives it a wider research-application footprint than GHK-Cu in non-skin tissue research.

Both GHK-Cu and BPC-157 ship from Regena Peptides only after independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds are published on the Regena Peptides lab reports page so a research-peptide buyer can audit the analytical detail before purchase. The /trust/how-to-read-a-coa reference walks through every field on a modern Regena Peptides COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. GHK-Cu is particularly sensitive to light and to oxidation — minimise light exposure and avoid repeat freeze-thaw cycling. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration for both compounds.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both GHK-Cu and BPC-157 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose GHK-Cu when the protocol targets skin, wound-healing, hair-follicle or matrix-metalloproteinase-axis research — particularly when the copper-mediated signalling pathway is part of the experimental design. Researchers choose BPC-157 when the protocol targets broader tissue-repair, angiogenic-axis or non-skin tissue research, or when a multi-axis pharmacological profile is preferred.

For multi-compound comparator studies, the Regena Peptides consultations team will reserve matched-batch inventory of both GHK-Cu and BPC-157 against a project timeline so the experimental panel is sourced under a single analytical specification window.

Both GHK-Cu and BPC-157 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on the Regena Peptides site exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.